A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome

Dysregulation of mTOR Signaling in Fragile X Syndrome

Ali Sharma, Charles A. Hoeffer, Yukihiro Takayasu et al. · Journal of Neuroscience · 2010 · 564 citations · Full text

Life Sciences, Molecular Biology, Neurobiology +17

Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study—a randomized controlled trial

Daniela Mastroiacovo, Catherine Kwik‐Uribe, Davide Grassi et al. · American Journal of Clinical Nutrition · 2014 · 334 citations · Full text

Agriculture, Nutrition, Nutritional Sciences +14

Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial

Elizabeth Berry‐Kravis, David Hessl, Barbara Rathmell et al. · Science Translational Medicine · 2012 · 325 citations · Full text

Medicine, Neuroscience, Pharmacotherapy +17

Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial

Rafael de la Torre, Susana Solá, Gimena Hernández et al. · The Lancet Neurology · 2016 · 286 citations

Medicine, Neurology, Neuroscience +9

Epigallocatechin‐3‐gallate, a DYRK1A inhibitor, rescues cognitive deficits in <scp>D</scp>own syndrome mouse models and in humans

Rafael de la Torre, Susana Solá, Meritxell Pons‐Espinal et al. · Molecular Nutrition & Food Research · 2013 · 279 citations

Life Sciences, Genetics, Neuroscience +17